GEN Exclusives

More »

GEN News Highlights

More »
Sep 27, 2013

SBIR Awards Etubics $1.5M to Manufacture Breast Cancer Immunotherapy

  • Etubics has received an approximately $1.5 million contract from the Small Business Innovation Research Development Center of the National Cancer Institute to manufacture its breast cancer immunotherapeutic, ETBX-021. The money will be used to generate the data required to support an IND application of ETBX-021 GMP product for a Phase I/II clinical trial.

    ETBX-021 utilizes the Etubics Platform, which is stealth to the immune system and has the ability to deliver a long lasting active immune response against cancer targets, educating the immune system's T-cells to act as if the cancer was a simple virus, according to the company.

    Etubics reported that preclinical studies have shown ETBX-021 can induce not only the traditional antibody response, but also potent cell-mediated immunity against HER2/neu tumors. Additionally, ETBX-021 prevented establishment of HER2/neu-expressing tumors and significantly inhibited progression of established tumors in mice models, the company said.

    The award follows another grant Etubics received in July of approximately $1.03 million from the National Institute of Health to research and develop a therapeutic vaccine for HIV/human papilloma virus associated oropharyngeal and tonsillar malignancy.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?